We identify SNS-032, a recently reported antagonist of CDK2/7/9 that exerts anti-tumor activities in multiple cancers 21-24, as an outstanding inducer of SIX1 degradation by downregulating expression of USP1 and triggering K48-linked ubiquitination of SIX1. Here, SIX1 is linked to neoplasm.